AUPH
Aurinia Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.05B
P/E Ratio
7.40
EPS
$2.13
Beta
1.45
52W High
$16.88
52W Low
$7.29
50-Day MA
$15.07
200-Day MA
$13.82
Dividend Yield
—
Profit Margin
101.50%
Forward P/E
22.12
PEG Ratio
0.00
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is headquartered in Victoria, Canada.
Fundamentals
| Revenue (TTM) | $283.06M |
| Gross Profit (TTM) | $217.88M |
| EBITDA | $135.71M |
| Operating Margin | 55.70% |
| Return on Equity | 59.90% |
| Return on Assets | 11.20% |
| Revenue/Share (TTM) | $2.11 |
| Book Value | $4.39 |
| Price-to-Book | 3.43 |
| Price-to-Sales (TTM) | 7.24 |
| EV/Revenue | 5.9 |
| EV/EBITDA | 12.12 |
| Quarterly Earnings Growth (YoY) | 15073.00% |
| Quarterly Revenue Growth (YoY) | 28.80% |
| Shares Outstanding | $129.94M |
| Float | $130.55M |
| % Insiders | 7.37% |
| % Institutions | 57.49% |
Historical Volatility
HV 10-Day
40.91%
HV 20-Day
30.78%
HV 30-Day
37.26%
HV 60-Day
34.87%
HV Rank
46.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($17.00 target)
4
Buy3
HoldMore HEALTHCARE Stocks
Data last updated: 5/5/2026